"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
| Descriptor ID |
D000960
|
| MeSH Number(s) |
D27.505.519.186.071 D27.505.954.557.500
|
| Concept/Terms |
Hypolipidemic Agents- Hypolipidemic Agents
- Agents, Hypolipidemic
- Antihyperlipidemics
- Hypolipidemic Drugs
- Drugs, Hypolipidemic
- Antilipemic Drugs
- Drugs, Antilipemic
- Antilipemics
- Antihyperlipemics
- Antilipemic Agents
- Agents, Antilipemic
|
Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".
This graph shows the total number of publications written about "Hypolipidemic Agents" by people in this website by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 3 | 0 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 4 | 0 | 4 |
| 2008 | 3 | 0 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2015 | 3 | 0 | 3 |
| 2016 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.
-
Yang X, Dai J, Zhong Y, Wei X, Wu M, Zhang Y, Huang A, Wang L, Huang Y, Zhang C, Chen X, Xiao H. Characterization of insoluble dietary fiber from three food sources and their potential hypoglycemic and hypolipidemic effects. Food Funct. 2021 Jul 21; 12(14):6576-6587.
-
Mercado-Lubo R, Yarzebski J, Lessard D, Gore J, Goldberg RJ. Changing Trends in the Landscape of Patients Hospitalized With Acute Myocardial Infarction (2001 to 2011) (from the Worcester Heart Attack Study). Am J Cardiol. 2020 03 01; 125(5):673-677.
-
Cannon CP, Khan I, Klimchak AC, Sanchez RJ, Sasiela WJ, Massaro JM, D'Agostino RB, Reynolds MR. Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. Am Heart J. 2019 10; 216:30-41.
-
Schreiner PJ, Jacobs DR, Wong ND, Kiefe CI. Twenty-Five Year Secular Trends in Lipids and Modifiable Risk Factors in a Population-Based Biracial Cohort: The Coronary Artery Risk Development in Young Adults (CARDIA) Study, 1985-2011. J Am Heart Assoc. 2016 07 05; 5(7).
-
Awad HH, Tisminetzky M, Metry D, McManus D, Yarzebski J, Gore JM, Goldberg RJ. Magnitude, treatment, and impact of diabetes mellitus in patients hospitalized with non-ST segment elevation myocardial infarction: A community-based study. Diab Vasc Dis Res. 2016 Jan; 13(1):13-20.
-
Yang S, Lu J, Eaton CB, Harpe S, Lapane KL. The Choice of Analytical Strategies in Inverse-Probability-of-Treatment-Weighted Analysis: A Simulation Study. Am J Epidemiol. 2015 Sep 15; 182(6):520-7.
-
Zachariah JP, McNeal CJ, Copeland LA, Fang-Hollingsworth Y, Stock EM, Sun F, Song JJ, Gregory ST, Tom JO, Wright EA, VanWormer JJ, Cassidy-Bushrow AE. Temporal trends in lipid screening and therapy among youth from 2002 to 2012. J Clin Lipidol. 2015 Sep-Oct; 9(5 Suppl):S77-87.
-
Bajaj R, Chhabra L, Kruger M, Kumar D. Mobile complex atherosclerotic aortic plaque. BMJ Case Rep. 2013 Apr 20; 2013.
-
Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant. 2012 Aug; 12(8):1975-82.
-
Carey KM, Comee MR, Donovan JL, Kanaan AO. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. Ann Pharmacother. 2012 May; 46(5):688-95.